Viking Therapeutics Inc [VKTX] stock is trading at $66.73, up 6.24%. An important factor to consider is whether the stock is rising or falling in short-term value. The VKTX shares have gain 23.28% over the last week, with a monthly amount glided 14.66%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Viking Therapeutics Inc [NASDAQ: VKTX] stock has seen the most recent analyst activity on September 11, 2024, when JP Morgan initiated its Overweight rating and assigned the stock a price target of $80. Previously, Morgan Stanley started tracking the stock with Overweight rating on June 27, 2024, and set its price target to $105. On May 16, 2024, upgrade upgraded it’s rating to Strong Buy and revised its price target to $116 on the stock. Oppenheimer reiterated its Outperform rating and increased its price target to $138 on March 26, 2024. Jefferies initiated its recommendation with a Buy and recommended $110 as its price target on March 07, 2024. Oppenheimer reiterated a Outperform rating for this stock on February 28, 2024, and upped its price target to $116.
Viking Therapeutics Inc [VKTX] stock has fluctuated between $8.28 and $99.41 over the past year. Currently, Wall Street analysts expect the stock to reach $100.5 within the next 12 months. Viking Therapeutics Inc [NASDAQ: VKTX] shares were valued at $66.73 at the most recent close of the market. An investor can expect a potential return of 50.61% based on the average VKTX price forecast.
Analyzing the VKTX fundamentals
Gross Profit Margin for this corporation currently stands at 0.32% with Operating Profit Margin at -285.96%, Pretax Profit Margin comes in at -221.89%, and Net Profit Margin reading is -221.89%. To continue investigating profitability, this company’s Return on Assets is posted at -0.1, Equity is -0.15 and Total Capital is -0.14. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 63.59 points at the first support level, and at 60.45 for the second support level. However, for the 1st resistance point, the stock is sitting at 68.90, and for the 2nd resistance point, it is at 71.08.
Ratios To Look Out For
For context, Viking Therapeutics Inc’s Current Ratio is 37.69. On the other hand, the Quick Ratio is 37.69, and the Cash Ratio is 1.75.
Transactions by insiders
Recent insider trading involved Lian Brian, President & CEO, that happened on Aug 21 ’24 when 1000.0 shares were sold. Director, SINGLETON J MATTHEW completed a deal on Aug 21 ’24 to sell 5700.0 shares. Meanwhile, Officer Lian Brian bought 1000.0 shares on Aug 21 ’24.
